cagrilintide and semaglutide 2.4 mg Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit PDF] Safety, tolerability, pharmacokinetics, and

This protocol simplicity is one reason this escalation produces high adherence rates in clinical trials and why it translates well to research applications

Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the exenatide study of cardiovascular event lowering (EXSCEL)

In the landmark 68-week STEP1 obesity trial, participants on 2.4mg recorded a mean body-weight reduction of 14.9%, versus 2.4% on placebo[1]. 50% lost 15% or more of their body weight, and 69% lost at least 10%[1]

Ozempic helps lower blood sugar levels by stimulating insulin production and reducing glucose production in the liver